HartungHPAktasOBoykoAN.Alemtuzumab: A new therapy for active relapsing-remitting multiple sclerosis. Mult Scler2015; 21: 22–34.
2.
CohenJAColesAJArnoldDL. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet2012; 380: 1819–1828.
3.
ColesAJTwymanCLArnoldDL. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet2012; 380: 1829–1839.
4.
RauDLangMHarthA. Listeria meningitis complicating alemtuzumab treatment in multiple sclerosis: Report of two cases. Int J Mol Sci2015; 16: 14669–14676.
5.
PenkertHDelbridgeCWantiaN. Fulminant central nervous system nocardiosis in a patient treated with alemtuzumab for relapsing-remitting multiple sclerosis. JAMA Neurol2016; 73: 757–759.
